ascendis pharma glp-1 receptor agonist Novo inks deal to develop long-acting GLP-1, other metabolic drugs GLP-1 Receptor Agonist Market Valued
Description
In clinical trials, people using GLP-1 drugs lost an average of about 10 pounds more than people using a placebo
Are they right for me
The GLP-1 Receptor Agonist market size is expected to reach $18.32 billion in 2030 at a CAGR of 5.4%, driven by rising prevalence of diabetes.
Learn how GLP-1 medications affect hunger, fullness, blood sugar, and weight loss, and why they are more than simple appetite suppressants.
IntroductionGlucagon-like peptide-1 receptor agonists (GLP-1 RA) are novel agents with proven cardiovascular (CV) benefits
Can tirzepatide cause anxiety
